Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD

Neurology

Volumn 84, Issue 7, 2015, Pages 645-653

  Serafin, Alice ^a,b   Foco, Luisa ^a,b   Zanigni, Stefano ^a,b,c   Blankenburg, Hagen ^a,b   Picard, Anne ^a,b   Zanon, Alessandra ^a,b   Giannini, Giulia ^a,b   Pichler, Irene ^a,b   Facheris, Maurizio F ^a,b   Cortelli, Pietro ^d   Pramstaller, Peter P ^a,b,c   Hicks, Andrew A ^a,b   Domingues, Francisco S ^a,b   Schwienbacher, Christine ^a,b  

^a University of Lubeck   (Italy)

^b UNIVERSITY OF LÜBECK   (Germany)

^c General Central Hospital   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LEVODOPA; MICRORNA; MICRORNA 103A 3P; MICRORNA 29A; MICRORNA 29A 3P; MICRORNA 29B 3P; MICRORNA 30A 5P; MICRORNA 30B 5P; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; MIRN103 MICRORNA, HUMAN; MIRN29 MICRORNA, HUMAN; MIRN30 MICRORNA, HUMAN; PHARMACOLOGICAL BIOMARKER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; PARKINSON DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGED; BLOOD; COMPUTER SIMULATION;

AGED; ANTIPARKINSON AGENTS; BIOMARKERS, PHARMACOLOGICAL; COMPUTER SIMULATION; FEMALE; HUMANS; LEVODOPA; MALE; MICRORNAS; PARKINSON DISEASE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84923239930     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001258     Document Type: Article

References (40)

1. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47:S2-S9; discussion S9-S11.
2. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 2003;991:1-14.
3. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol 2013;9:445-454.
4. Shtilbans A, Henchcliffe C. Biomarkers in Parkinson's disease: an update. Curr Opin Neurol 2012;25:460-465.
5. Heman-Ackah SM, Hallegger M, Rao MS, Wood MJ. RISC in PD: the impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis. Front Mol Neurosci 2013;6:40.
6. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006;147:126-132.
7. Margis R, Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinson's disease. J Biotechnol 2011;152:96-101.
8. Martins M, Rosa A, Guedes LC, et al. Convergence of miRNA expression profiling, alpha-synuclein interaction and GWAS in Parkinson's disease. PLoS One 2011;6: e25443.
9. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
10. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004;64:5245-5250.
11. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
12. Silver N, Best S, Jiang J, Thein SL. Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol Biol 2006;7:33.
13. Bustin SA, Benes V, Garson JA, et al. TheMIQE guidelines: minimum information for publication of quantitative realtime PCR experiments. Clin Chem 2009;55:611-622.
14. Moreau Y, Tranchevent LC. Computational tools for prioritizing candidate genes: boosting disease gene discovery. Nat Rev Genet 2012;13:523-536.
15. Aerts S, Lambrechts D, Maity S, et al. Gene prioritization through genomic data fusion. Nat Biotechnol 2006;24: 537-544.
16. Vergoulis T, Vlachos IS, Alexiou P, et al. TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res 2012;40:D222-D229.
17. Hsu SD, Lin FM, Wu WY, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 2011;39:D163-D169.
18. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk - database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011;44: 839-847.
19. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009;37:D105-D110.
20. Reczko M, Maragkakis M, Alexiou P, Grosse I, Hatzigeorgiou AG. Functional microRNA targets in protein coding sequences. Bioinformatics 2012;28:771-776.
21. Vejnar CE, Zdobnov EM. MiRmap: comprehensive prediction of microRNA target repression strength. Nucleic Acids Res 2012;40:11673-11683.
22. Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 2008;14:1012-1017.
23. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
24. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010;11:R90.
25. Arduino DM, Esteves AR, Cardoso SM. Mitochondrial fusion/fission, transport and autophagy in Parkinson's disease: when mitochondria get nasty. Parkinsons Dis 2011; 2011:767230.
26. Moncini S, Salvi A, Zuccotti P, et al. The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration. PLoS One 2011;6:e20038.
27. Herrera BM, Lockstone HE, Taylor JM, et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010;53:1099-1109.
28. Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011;474: 649-653.
29. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013;136:374-384.
30. Filatova EV, Alieva AK, Shadrina MI, Slominsky PA. Micro- RNAs: possible role in pathogenesis of Parkinson's disease. Biochemistry 2012;77:813-819.
31. Shehadeh L, Mitsi G, Adi N, Bishopric N, Papapetropoulos S. Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects. Mov Disord 2009; 24:204-210.
32. Chandrasekaran S, Bonchev D. A network view on Parkinson's disease. Comput Struct Biotechnol J 2013;7: e201304004.
33. Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet 2010;6:e1000795.
34. Wilhelmus MM, Nijland PG, Drukarch B, de Vries HE, van Horssen J. Involvement and interplay of parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders. Free Radic Biol Med 2012;53:983-992.
35. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM. Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev 2013;2013: 683920.
36. Kitagishi Y, Wada Y, Matsuda S. Roles of PI3K/AKT/PTEN pathway in the pathogenesis of Parkinson's disease and the neuropsychiatric symptoms. Int Neuropsychiatr Dis J 2014;2: 1-12.
37. Mandillo S, Golini E, Marazziti D, Di Pietro C, Matteoni R, Tocchini-Valentini GP. Mice lacking the Parkinson's related GPR37/PAEL receptor show non-motor behavioral phenotypes: age and gender effect. Genes Brain Behav 2013;12:465-477.
38. Karic A, Terzic R, Karic A, Peterlin B. Identifying candidate genes for Parkinson's disease by integrative genomics method. Biochem Med 2011;21:174-181.
39. Barcia C, Ros CM, Annese V, et al. ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Sci Rep 2012;2:809.
40. van der Heide LP, Smidt MP. The BCL2 code to dopaminergic development and Parkinson's disease. Trends Mol Med 2013;19:211-216.